Pub Date : 2024-04-01DOI: 10.1016/j.rgmxen.2023.04.012
S. Özdemir , İ. Altunok , A. Özkan , M.M. İslam , A. Algın , S.E. Eroğlu , G. Aksel
Introduction and aims
We aimed to investigate changes in initial platelet indices in patients arriving at the emergency department with acute cholecystitis.
Material and methods
A retrospective case-control study was conducted at a tertiary care teaching hospital. Demographics, comorbidities, laboratory data, length of hospital stay, and mortality data for the acute cholecystitis group were retrospectively obtained from the hospital digital database. Platelet count, mean platelet volume, plateletcrit, platelet distribution width, and platelet mass index were collected.
Results
A total of 553 patients with acute cholecystitis were the study cases, and 541 hospital employees were the study controls. According to the results of the multivariate analysis of the platelet indices studied, only mean platelet volume and platelet distribution width showed significant differences between the two groups (adjusted odds ratio: 2, 95% confidence interval: 1.4−2.7, p < 0.001 and adjusted odds ratio: 5.88, 95% confidence interval: 2.44−14.4, p < 0.001, respectively). The multivariate regression model created had an area under the curve of 0.969 in the prediction of acute cholecystitis (accuracy: 0.917, sensitivity: 89%, and specificity: 94.5%).
Conclusion
The study results indicate that the initial mean platelet volume and platelet distribution width were independent predictors of acute cholecystitis.
{"title":"Relationship between platelet indices in acute cholecystitis: A case-control study","authors":"S. Özdemir , İ. Altunok , A. Özkan , M.M. İslam , A. Algın , S.E. Eroğlu , G. Aksel","doi":"10.1016/j.rgmxen.2023.04.012","DOIUrl":"10.1016/j.rgmxen.2023.04.012","url":null,"abstract":"<div><h3>Introduction and aims</h3><p>We aimed to investigate changes in initial platelet indices in patients arriving at the emergency department with acute cholecystitis.</p></div><div><h3>Material and methods</h3><p>A retrospective case-control study was conducted at a tertiary care teaching hospital. Demographics, comorbidities, laboratory data, length of hospital stay, and mortality data for the acute cholecystitis group were retrospectively obtained from the hospital digital database. Platelet count, mean platelet volume, plateletcrit, platelet distribution width, and platelet mass index were collected.</p></div><div><h3>Results</h3><p>A total of 553 patients with acute cholecystitis were the study cases, and 541 hospital employees were the study controls. According to the results of the multivariate analysis of the platelet indices studied, only mean platelet volume and platelet distribution width showed significant differences between the two groups (adjusted odds ratio: 2, 95% confidence interval: 1.4−2.7, p < 0.001 and adjusted odds ratio: 5.88, 95% confidence interval: 2.44−14.4, p < 0.001, respectively). The multivariate regression model created had an area under the curve of 0.969 in the prediction of acute cholecystitis (accuracy: 0.917, sensitivity: 89%, and specificity: 94.5%).</p></div><div><h3>Conclusion</h3><p>The study results indicate that the initial mean platelet volume and platelet distribution width were independent predictors of acute cholecystitis.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 232-236"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000701/pdfft?md5=f958187e9abb48f2043d2c42e27170e2&pid=1-s2.0-S2255534X23000701-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9758272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.rgmxen.2022.09.002
C.E. Lombo-Moreno , O.M. Muñoz-Velandia , D.G. Fernández-Ávila , J.E. Barahona-Correa , V. López-Ramírez , A. Rodriguez-Varon
Introduction and aim
The majority of patients with inflammatory bowel disease (IBD) seek information about their disease on the Internet. The reliability, comprehensiveness, and quality of said information in Spanish has not previously been studied.
Materials and methods
An analytic observational study was conducted that included YouTube® videos on IBD available in Spanish, describing general characteristics, engagement, and sources. Standard tools for evaluating reliability (DISCERN), comprehensiveness, and overall quality (Global Quality Score, GQS) were employed.
Results
One hundred videos were included. Eighty-eight videos consisted of information produced by healthcare professionals (group 1) and 12 included patient opinions (group 2). There were no differences in the median scores for reliability (DISCERN 3 vs 3, p = 0.554) or comprehensiveness (3 vs 2.5, p = 0.768) between the two groups, but there was greater overall quality in the group 2 videos (GQS 3 vs 4, p = 0.007). Reliability was higher for the videos produced by professional organizations (DISCERN 4; IQR 3–4), when compared with healthcare information websites and for-profit agencies (DISCERN 3; IQR 2.5–3.5) (p < 0.001), but the videos with healthcare information website and for-profit sources had a higher quality score (GQS 3 vs 4, p < 0.001). Comprehensiveness scores were similar.
Conclusion
The majority of YouTube® videos in Spanish on IBD have good reliability, comprehensiveness, and quality. Reliability was greater for the videos produced by professional organizations, whereas quality was higher for those created from healthcare information websites and for-profit agencies.
引言和目的大多数炎症性肠病(IBD)患者都在互联网上寻求有关其疾病的信息。材料与方法我们开展了一项分析性观察研究,其中包括 YouTube® 上有关 IBD 的西班牙语视频,描述了这些视频的一般特征、参与度和来源。研究采用了评估可靠性(DISCERN)、全面性和总体质量(全球质量评分,GQS)的标准工具。其中 88 个视频由医护人员制作(第 1 组),12 个视频包含患者意见(第 2 组)。两组视频在可靠性(DISCERN 3 vs 3,p = 0.554)和全面性(3 vs 2.5,p = 0.768)的中位数得分上没有差异,但第二组视频的整体质量更高(GQS 3 vs 4,p = 0.007)。与医疗保健信息网站和营利机构(DISCERN 3;IQR 2.5-3.5)相比,专业组织制作的视频(DISCERN 4;IQR 3-4)可靠性更高(p <0.001),但医疗保健信息网站和营利机构制作的视频质量得分更高(GQS 3 vs 4,p <0.001)。结论大多数 YouTube® 西班牙语 IBD 视频具有良好的可靠性、全面性和质量。专业组织制作的视频可靠性更高,而医疗保健信息网站和营利机构制作的视频质量更高。
{"title":"YouTube® in Spanish as a source of information for patients with inflammatory bowel disease","authors":"C.E. Lombo-Moreno , O.M. Muñoz-Velandia , D.G. Fernández-Ávila , J.E. Barahona-Correa , V. López-Ramírez , A. Rodriguez-Varon","doi":"10.1016/j.rgmxen.2022.09.002","DOIUrl":"10.1016/j.rgmxen.2022.09.002","url":null,"abstract":"<div><h3>Introduction and aim</h3><p>The majority of patients with inflammatory bowel disease (IBD) seek information about their disease on the Internet. The reliability, comprehensiveness, and quality of said information in Spanish has not previously been studied.</p></div><div><h3>Materials and methods</h3><p>An analytic observational study was conducted that included YouTube® videos on IBD available in Spanish, describing general characteristics, engagement, and sources. Standard tools for evaluating reliability (DISCERN), comprehensiveness, and overall quality (Global Quality Score, GQS) were employed.</p></div><div><h3>Results</h3><p>One hundred videos were included. Eighty-eight videos consisted of information produced by healthcare professionals (group 1) and 12 included patient opinions (group 2). There were no differences in the median scores for reliability (DISCERN 3 vs 3, <em>p</em> = 0.554) or comprehensiveness (3 vs 2.5, <em>p</em> = 0.768) between the two groups, but there was greater overall quality in the group 2 videos (GQS 3 vs 4, <em>p</em> = 0.007). Reliability was higher for the videos produced by professional organizations (DISCERN 4; IQR 3–4), when compared with healthcare information websites and for-profit agencies (DISCERN 3; IQR 2.5–3.5) (<em>p</em> < 0.001), but the videos with healthcare information website and for-profit sources had a higher quality score (GQS 3 vs 4, <em>p</em> < 0.001). Comprehensiveness scores were similar.</p></div><div><h3>Conclusion</h3><p>The majority of YouTube® videos in Spanish on IBD have good reliability, comprehensiveness, and quality. Reliability was greater for the videos produced by professional organizations, whereas quality was higher for those created from healthcare information websites and for-profit agencies.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 176-185"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000427/pdfft?md5=122201f376a5112623f9060acbcca115&pid=1-s2.0-S2255534X23000427-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9442948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-04-01DOI: 10.1016/j.rgmxen.2023.05.007
J. Bandera Quijano
{"title":"YouTube® as a source of information for patients with gastrointestinal disease","authors":"J. Bandera Quijano","doi":"10.1016/j.rgmxen.2023.05.007","DOIUrl":"10.1016/j.rgmxen.2023.05.007","url":null,"abstract":"","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 173-175"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000646/pdfft?md5=8dcc6620b4083701e8c067f00d486cf4&pid=1-s2.0-S2255534X23000646-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9568808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.rgmxen.2022.07.002
E. Baran , M.V. D’Ascenzo , J.D. Bosia , P. Montaña
Introduction and aims
Cystic fibrosis (CF) is a genetic disease whose gastrointestinal compromise mainly involves the pancreas, bile ducts, and liver. Our aim was to analyze abdominal ultrasound findings.
Methods
A retrospective, descriptive study was conducted on adults (patients ≥ 16 years of age) diagnosed with CF, within the time frame of 2006-2019. Clinical and genetic parameters, body mass index, forced expiratory volume in one second, pancreatic insufficiency, CF-related diabetes, cirrhosis secondary to CF, and abdominal ultrasound images were analyzed.
Results
Seventy patients, 39 of whom were men (55.8%), had a mean age of 27 years and a mean body mass index of 21.3 ± 2.8 kg/m2 (r: 17-30.9). Forty-seven (67.1%) presented with pancreatic insufficiency, 6 (8.5%) with cirrhosis secondary to CF, and 21 (30%) had CF-related diabetes. Median forced expiratory volume in one second was 47% and the F508del mutation was found in 56.1%. Images of the pancreas: no pathologic findings in 49 (70%), increased echogenicity in 18 (25.7%), and cysts in 3 (4.3%). Gallbladder images: microgallbladder in 3 (4.2%), biliary sludge in 2 (2.8%), gallstones in 7 (10%), and a history of cholecystectomy in 4 (5.8%). Liver and spleen images: no pathologic findings in 47 (67.2%), homogeneous hepatomegaly with splenomegaly in 2 (2.8%), a heterogeneous pattern of the parenchyma in 11 (15.8%), increased echogenicity in 4 (5.7%), and heterogeneous echo patterns, lobulated liver contour, and splenomegaly in 6 (8.5%).
Conclusion
Abdominal ultrasound is a safe, low-cost technique that enables the identification of some degree of chronic liver and pancreatic diseases, improving the approach and follow-up decisions in adult patients with CF.
{"title":"Abdominal ultrasound findings in adult patients with cystic fibrosis","authors":"E. Baran , M.V. D’Ascenzo , J.D. Bosia , P. Montaña","doi":"10.1016/j.rgmxen.2022.07.002","DOIUrl":"10.1016/j.rgmxen.2022.07.002","url":null,"abstract":"<div><h3>Introduction and aims</h3><p>Cystic fibrosis (CF) is a genetic disease whose gastrointestinal compromise mainly involves the pancreas, bile ducts, and liver. Our aim was to analyze abdominal ultrasound findings.</p></div><div><h3>Methods</h3><p>A retrospective, descriptive study was conducted on adults (patients ≥ 16 years of age) diagnosed with CF, within the time frame of 2006-2019. Clinical and genetic parameters, body mass index, forced expiratory volume in one second, pancreatic insufficiency, CF-related diabetes, cirrhosis secondary to CF, and abdominal ultrasound images were analyzed.</p></div><div><h3>Results</h3><p>Seventy patients, 39 of whom were men (55.8%), had a mean age of 27 years and a mean body mass index of 21.3 ± 2.8 kg/m<sup>2</sup> (r: 17-30.9). Forty-seven (67.1%) presented with pancreatic insufficiency, 6 (8.5%) with cirrhosis secondary to CF, and 21 (30%) had CF-related diabetes. Median forced expiratory volume in one second was 47% and the F508del mutation was found in 56.1%. Images of the pancreas: no pathologic findings in 49 (70%), increased echogenicity in 18 (25.7%), and cysts in 3 (4.3%). Gallbladder images: microgallbladder in 3 (4.2%), biliary sludge in 2 (2.8%), gallstones in 7 (10%), and a history of cholecystectomy in 4 (5.8%). Liver and spleen images: no pathologic findings in 47 (67.2%), homogeneous hepatomegaly with splenomegaly in 2 (2.8%), a heterogeneous pattern of the parenchyma in 11 (15.8%), increased echogenicity in 4 (5.7%), and heterogeneous echo patterns, lobulated liver contour, and splenomegaly in 6 (8.5%).</p></div><div><h3>Conclusion</h3><p>Abdominal ultrasound is a safe, low-cost technique that enables the identification of some degree of chronic liver and pancreatic diseases, improving the approach and follow-up decisions in adult patients with CF.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 19-24"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X22000883/pdfft?md5=76aaf7e16143cb2d9e41736d9fb55a5f&pid=1-s2.0-S2255534X22000883-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40539226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.rgmxen.2023.08.008
I. Aiza-Haddad , L.E. Cisneros-Garza , O. Morales-Gutiérrez , R. Malé-Velázquez , M.T. Rizo-Robles , R. Alvarado-Reyes , L.A. Barrientos-Quintanilla , F. Betancourt-Sánchez , E. Cerda-Reyes , R. Contreras-Omaña , M.B. Dehesa-Violante , N.C. Flores-García , D. Gómez-Almaguer , M.F. Higuera-de la Tijera , M.A. Lira-Pedrin , J.E. Lira-Vera , H. Manzano-Cortés , D.E. Meléndez-Mena , M.R. Muñoz-Ramírez , J.L. Pérez-Hernández , J.F. Sánchez-Ávila
Coagulation management in the patient with cirrhosis has undergone a significant transformation since the beginning of this century, with the concept of a rebalancing between procoagulant and anticoagulant factors. The paradigm that patients with cirrhosis have a greater bleeding tendency has changed, as a result of this rebalancing. In addition, it has brought to light the presence of complications related to thrombotic events in this group of patients.
These guidelines detail aspects related to pathophysiologic mechanisms that intervene in the maintenance of hemostasis in the patient with cirrhosis, the relevance of portal hypertension, mechanical factors for the development of bleeding, modifications in the hepatic synthesis of coagulation factors, and the changes in the reticuloendothelial system in acute hepatic decompensation and acute-on-chronic liver failure. They address new aspects related to the hemorrhagic complications in patients with cirrhosis, considering the risk for bleeding during diagnostic or therapeutic procedures, as well as the usefulness of different tools for diagnosing coagulation and recommendations on the pharmacologic treatment and blood-product transfusion in the context of hemorrhage. These guidelines also update the knowledge regarding hypercoagulability in the patient with cirrhosis, as well as the efficacy and safety of treatment with the different anticoagulation regimens. Lastly, they provide recommendations on coagulation management in the context of acute-on-chronic liver failure, acute liver decompensation, and specific aspects related to the patient undergoing liver transplantation.
{"title":"Guidelines for the management of coagulation disorders in patients with cirrhosis","authors":"I. Aiza-Haddad , L.E. Cisneros-Garza , O. Morales-Gutiérrez , R. Malé-Velázquez , M.T. Rizo-Robles , R. Alvarado-Reyes , L.A. Barrientos-Quintanilla , F. Betancourt-Sánchez , E. Cerda-Reyes , R. Contreras-Omaña , M.B. Dehesa-Violante , N.C. Flores-García , D. Gómez-Almaguer , M.F. Higuera-de la Tijera , M.A. Lira-Pedrin , J.E. Lira-Vera , H. Manzano-Cortés , D.E. Meléndez-Mena , M.R. Muñoz-Ramírez , J.L. Pérez-Hernández , J.F. Sánchez-Ávila","doi":"10.1016/j.rgmxen.2023.08.008","DOIUrl":"https://doi.org/10.1016/j.rgmxen.2023.08.008","url":null,"abstract":"<div><p>Coagulation management in the patient with cirrhosis has undergone a significant transformation since the beginning of this century, with the concept of a rebalancing between procoagulant and anticoagulant factors. The paradigm that patients with cirrhosis have a greater bleeding tendency has changed, as a result of this rebalancing. In addition, it has brought to light the presence of complications related to thrombotic events in this group of patients.</p><p>These guidelines detail aspects related to pathophysiologic mechanisms that intervene in the maintenance of hemostasis in the patient with cirrhosis, the relevance of portal hypertension, mechanical factors for the development of bleeding, modifications in the hepatic synthesis of coagulation factors, and the changes in the reticuloendothelial system in acute hepatic decompensation and acute-on-chronic liver failure. They address new aspects related to the hemorrhagic complications in patients with cirrhosis, considering the risk for bleeding during diagnostic or therapeutic procedures, as well as the usefulness of different tools for diagnosing coagulation and recommendations on the pharmacologic treatment and blood-product transfusion in the context of hemorrhage. These guidelines also update the knowledge regarding hypercoagulability in the patient with cirrhosis, as well as the efficacy and safety of treatment with the different anticoagulation regimens. Lastly, they provide recommendations on coagulation management in the context of acute-on-chronic liver failure, acute liver decompensation, and specific aspects related to the patient undergoing liver transplantation.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 144-162"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X24000124/pdfft?md5=c96d61fbcb22480ab06061e16a1fb62d&pid=1-s2.0-S2255534X24000124-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140558985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.rgmxen.2021.11.017
A. Jena , N. Grover , P. Bhatia , M. Singh , D. Lad , K.K. Prasad , H. Singh , U. Dutta , V. Sharma
Introduction and aim
Thiopurine-related leukopenia is associated with polymorphisms in the thiopurine methyltransferase (TPMT) and nucleoside diphosphate-linked moiety X type motif 15 (NUDT15) genes. However, those polymorphisms explain only a fraction of thiopurine-related leukopenia. Our aim was to study the role of an inosine triphosphate pyrophosphatase (ITPA) polymorphism in patients with inflammatory bowel disease (IBD) and thiopurine-related leukopenia that was unexplained by the TPMT and NUDT15 polymorphisms.
Material and methods
We enrolled consecutive IBD patients on thiopurines (azathioprine or 6-mercaptopurine) from January 2019–March 2020, at a tertiary care center in North India. The presence of the ITPA (C.94C > A) polymorphism was evaluated in all patients, along with its association with thiopurine-related leukopenia.
Results
Of the 33 patients (from a total of 119 patients) that developed leukopenia, 8 had the TPMT (n = 1) or NUDT15 (n = 7) polymorphism. Of the remaining 111 patients, their mean age was 36.36 ± 13.54 years and 57 (51.3%) were males. Twenty-five (21.01%) had unexplained leukopenia. The ITPA polymorphism was detected in 4 (16%) patients in the unexplained leukopenia group and 24 (27.9%) patients in the non-leukopenia group (p = 0.228). The odds ratio for predicting leukopenia with the ITPA polymorphism was 0.4921 (95% CI 0.1520–1.5830, p = 0.234).
Conclusion
The ITPA (C.94C > A) polymorphism was frequently detected in the study population but was not predictive for leukopenia in patients with IBD on thiopurine therapy.
{"title":"ITPA polymorphisms do not predict additional risk beyond TPMT and NUDT15 for thiopurine-induced cytopenia in inflammatory bowel disease","authors":"A. Jena , N. Grover , P. Bhatia , M. Singh , D. Lad , K.K. Prasad , H. Singh , U. Dutta , V. Sharma","doi":"10.1016/j.rgmxen.2021.11.017","DOIUrl":"10.1016/j.rgmxen.2021.11.017","url":null,"abstract":"<div><h3>Introduction and aim</h3><p>Thiopurine-related leukopenia is associated with polymorphisms in the thiopurine methyltransferase (TPMT) and nucleoside diphosphate-linked moiety X type motif 15 (NUDT15) genes. However, those polymorphisms explain only a fraction of thiopurine-related leukopenia. Our aim was to study the role of an inosine triphosphate pyrophosphatase (ITPA) polymorphism in patients with inflammatory bowel disease (IBD) and thiopurine-related leukopenia that was unexplained by the TPMT and NUDT15 polymorphisms.</p></div><div><h3>Material and methods</h3><p>We enrolled consecutive IBD patients on thiopurines (azathioprine or 6-mercaptopurine) from January 2019–March 2020, at a tertiary care center in North India. The presence of the ITPA (C.94C > A) polymorphism was evaluated in all patients, along with its association with thiopurine-related leukopenia.</p></div><div><h3>Results</h3><p>Of the 33 patients (from a total of 119 patients) that developed leukopenia, 8 had the TPMT (n = 1) or NUDT15 (n = 7) polymorphism. Of the remaining 111 patients, their mean age was 36.36 ± 13.54 years and 57 (51.3%) were males. Twenty-five (21.01%) had unexplained leukopenia. The ITPA polymorphism was detected in 4 (16%) patients in the unexplained leukopenia group and 24 (27.9%) patients in the non-leukopenia group (p = 0.228). The odds ratio for predicting leukopenia with the ITPA polymorphism was 0.4921 (95% CI 0.1520–1.5830, p = 0.234).</p></div><div><h3>Conclusion</h3><p>The ITPA (C.94C > A) polymorphism was frequently detected in the study population but was not predictive for leukopenia in patients with IBD on thiopurine therapy.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 25-30"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000063/pdfft?md5=3a7f13d141c58a93a6984dac6dd2af48&pid=1-s2.0-S2255534X23000063-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10625603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.rgmxen.2023.12.002
M.A. Valdovinos Díaz , M. Amieva-Balmori , R. Carmona-Sánchez , E. Coss-Adame , O. Gómez-Escudero , M. González-Martínez , F. Huerta-Iga , E. Morel-Cerda , J.M. Remes-Troche , J.L. Tamayo-de la Cuesta , G. Torres-Villalobos , L.R. Valdovinos-García , G. Vázquez-Elizondo , A.S. Villar-Chávez , J.A. Arenas-Martínez
Introduction
Gastroesophageal reflux disease (GERD) is very prevalent in the general population, with a broad spectrum of clinical manifestations, requiring accurate diagnosis and treatment.
Aim
The aim of this expert review is to establish good clinical practice recommendations for the diagnosis and personalized treatment of GERD.
Methods
The good clinical practice recommendations were produced by a group of experts in GERD, members of the Asociación Mexicana de Gastroenterología (AMG), after carrying out an extensive review of the published literature and discussing each recommendation at a face-to-face meeting. This document does not aim to be a clinical practice guideline with the methodology such a document requires.
Results
Fifteen experts on GERD formulated 27 good clinical practice recommendations for recognizing the symptoms and complications of GERD, the rational use of diagnostic tests and medical treatment, the identification and management of refractory GERD, the overlap with functional disorders, endoscopic and surgical treatment, and GERD in the pregnant woman, older adult, and the obese patient.
Conclusions
An accurate diagnosis of GERD is currently possible, enabling the prescription of a personalized treatment in patients with this condition. The goal of the good clinical practice recommendations by the group of experts from the AMG presented in this document is to aid both the general practitioner and specialist in the process of accurate diagnosis and treatment, in the patient with GERD.
{"title":"Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociación Mexicana de Gastroenterología","authors":"M.A. Valdovinos Díaz , M. Amieva-Balmori , R. Carmona-Sánchez , E. Coss-Adame , O. Gómez-Escudero , M. González-Martínez , F. Huerta-Iga , E. Morel-Cerda , J.M. Remes-Troche , J.L. Tamayo-de la Cuesta , G. Torres-Villalobos , L.R. Valdovinos-García , G. Vázquez-Elizondo , A.S. Villar-Chávez , J.A. Arenas-Martínez","doi":"10.1016/j.rgmxen.2023.12.002","DOIUrl":"https://doi.org/10.1016/j.rgmxen.2023.12.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Gastroesophageal reflux disease (GERD) is very prevalent in the general population, with a broad spectrum of clinical manifestations, requiring accurate diagnosis and treatment.</p></div><div><h3>Aim</h3><p>The aim of this expert review is to establish good clinical practice recommendations for the diagnosis and personalized treatment of GERD.</p></div><div><h3>Methods</h3><p>The good clinical practice recommendations were produced by a group of experts in GERD, members of the <em>Asociación Mexicana de Gastroenterología</em> (<em>AMG</em>), after carrying out an extensive review of the published literature and discussing each recommendation at a face-to-face meeting. This document does not aim to be a clinical practice guideline with the methodology such a document requires.</p></div><div><h3>Results</h3><p>Fifteen experts on GERD formulated 27 good clinical practice recommendations for recognizing the symptoms and complications of GERD, the rational use of diagnostic tests and medical treatment, the identification and management of refractory GERD, the overlap with functional disorders, endoscopic and surgical treatment, and GERD in the pregnant woman, older adult, and the obese patient.</p></div><div><h3>Conclusions</h3><p>An accurate diagnosis of GERD is currently possible, enabling the prescription of a personalized treatment in patients with this condition. The goal of the good clinical practice recommendations by the group of experts from the <em>AMG</em> presented in this document is to aid both the general practitioner and specialist in the process of accurate diagnosis and treatment, in the patient with GERD.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 121-143"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X24000112/pdfft?md5=3b5a5d1707194092fe42e4e167b15dea&pid=1-s2.0-S2255534X24000112-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140558905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.rgmxen.2023.05.006
E. Coss-Adame , J.M. Remes-Troche , R. Flores Rendón , J.L. Tamayo de la Cuesta , M.A. Valdovinos Díaz
Introduction
Chronic idiopathic constipation (CIC) negatively impacts quality of life and increases healthcare costs. Lubiprostone stimulates the secretion of intestinal fluid, in turn facilitating the passage of stools and alleviating associated symptoms. Lubiprostone has been available in Mexico since 2018, but its clinical efficacy has not been studied in a Mexican population.
Aim
To evaluate the efficacy of lubiprostone, assessed by changes in spontaneous bowel movement (SBM) frequency after one week of treatment with 24 μg oral lubiprostone (b.i.d.), as well as its safety, over four weeks of treatment.
Study
Randomized, double-blind, placebo-controlled study on 211 adults with CIC in Mexico.
Results
The increase in SBM frequency, after one week of treatment, was significantly higher in the lubiprostone group than in the placebo group (mean: 4.9 [SD: 4.45] vs. 3.0 [3.14], p = 0.020). Secondary efficacy endpoints revealed a significantly higher proportion of SBM frequency/week in the lubiprostone group at weeks 2, 3, and 4. There was a better response within 24 h after the first dose with lubiprostone vs. placebo (60.0% vs. 41.5%; OR: 2.08, CI95%: [1.19, 3.62], p = 0.009) and the lubiprostone group also had significant improvement, with respect to straining, stool consistency, abdominal bloating, and Satisfaction Index. The main adverse events were gastrointestinal disorders in 13 (12.4%) lubiprostone-treated subjects and 4 (3.8%) control subjects.
Conclusions
Our data confirm the efficacy and safety of lubiprostone for the treatment of CIC in a Mexican population. Lubiprostone treatment induces relief from the most bothersome symptoms associated with constipation.
{"title":"Efficacy and safety of lubiprostone for the treatment of chronic idiopathic constipation: A phase 3, randomized, placebo-controlled study","authors":"E. Coss-Adame , J.M. Remes-Troche , R. Flores Rendón , J.L. Tamayo de la Cuesta , M.A. Valdovinos Díaz","doi":"10.1016/j.rgmxen.2023.05.006","DOIUrl":"10.1016/j.rgmxen.2023.05.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Chronic idiopathic constipation (CIC) negatively impacts quality of life and increases healthcare costs. Lubiprostone stimulates the secretion of intestinal fluid, in turn facilitating the passage of stools and alleviating associated symptoms. Lubiprostone has been available in Mexico since 2018, but its clinical efficacy has not been studied in a Mexican population.</p></div><div><h3>Aim</h3><p>To evaluate the efficacy of lubiprostone, assessed by changes in spontaneous bowel movement (SBM) frequency after one week of treatment with 24 μg oral lubiprostone (b.i.d.), as well as its safety, over four weeks of treatment.</p></div><div><h3>Study</h3><p>Randomized, double-blind, placebo-controlled study on 211 adults with CIC in Mexico.</p></div><div><h3>Results</h3><p>The increase in SBM frequency, after one week of treatment, was significantly higher in the lubiprostone group than in the placebo group (mean: 4.9 [SD: 4.45] <em>vs.</em> 3.0 [3.14], <em>p</em> = 0.020). Secondary efficacy endpoints revealed a significantly higher proportion of SBM frequency/week in the lubiprostone group at weeks 2, 3, and 4. There was a better response within 24 h after the first dose with lubiprostone <em>vs.</em> placebo (60.0% <em>vs.</em> 41.5%; OR: 2.08, CI95%: [1.19, 3.62], <em>p</em> = 0.009) and the lubiprostone group also had significant improvement, with respect to straining, stool consistency, abdominal bloating, and Satisfaction Index. The main adverse events were gastrointestinal disorders in 13 (12.4%) lubiprostone-treated subjects and 4 (3.8%) control subjects.</p></div><div><h3>Conclusions</h3><p>Our data confirm the efficacy and safety of lubiprostone for the treatment of CIC in a Mexican population. Lubiprostone treatment induces relief from the most bothersome symptoms associated with constipation.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 70-79"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000622/pdfft?md5=7e45b855aeec9385f219176096c6fac8&pid=1-s2.0-S2255534X23000622-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9522517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.rgmxen.2024.01.001
E. Jasso-Baltazar , J. Ruiz-Manriquez , L.E. Zamora-Nava
{"title":"Peristomal varices: Another cause of bleeding in patients with portal hypertension","authors":"E. Jasso-Baltazar , J. Ruiz-Manriquez , L.E. Zamora-Nava","doi":"10.1016/j.rgmxen.2024.01.001","DOIUrl":"10.1016/j.rgmxen.2024.01.001","url":null,"abstract":"","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 165-166"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X24000094/pdfft?md5=049d8c866e53c942710a3e5de010846f&pid=1-s2.0-S2255534X24000094-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.1016/j.rgmxen.2023.02.002
R. Montalvo-Otivo , P. Vilcapoma , A. Murillo , C. Mathey , A. Olivera , G. Veliz , D. Estrella
Introduction
The treatment and diagnosis of chronic diarrhea in the immunocompromised patient depends on the ability to rapidly detect the etiologic agents.
Aims
Our aim was to evaluate the results of the FilmArray® gastrointestinal panel in patients newly diagnosed with HIV infection that presented with chronic diarrhea.
Material and methods
Utilizing nonprobability consecutive convenience sampling, 24 patients were included that underwent molecular testing for the simultaneous detection of 22 pathogens.
Results
In 24 HIV-infected patients with chronic diarrhea, enteropathogen bacteria were detected in 69% of the cases, parasites in 18%, and viruses in 13%. Enteropathogenic Escherichia coli and enteroaggregative Escherichia coli were the main bacteria identified, Giardia lamblia was found in 25%, and norovirus was the most frequent viral agent. The median number of infectious agents per patient was three (range of 0 to 7). The biologic agents not identified through the FilmArray® method were tuberculosis and fungi.
Conclusions
Several infectious agents were simultaneously detected through the FilmArray® gastrointestinal panel in patients with HIV infection and chronic diarrhea.
{"title":"Evaluation of chronic diarrhea in patients newly diagnosed with HIV infection through the FilmArray® gastrointestinal panel","authors":"R. Montalvo-Otivo , P. Vilcapoma , A. Murillo , C. Mathey , A. Olivera , G. Veliz , D. Estrella","doi":"10.1016/j.rgmxen.2023.02.002","DOIUrl":"10.1016/j.rgmxen.2023.02.002","url":null,"abstract":"<div><h3>Introduction</h3><p>The treatment and diagnosis of chronic diarrhea in the immunocompromised patient depends on the ability to rapidly detect the etiologic agents.</p></div><div><h3>Aims</h3><p>Our aim was to evaluate the results of the FilmArray® gastrointestinal panel in patients newly diagnosed with HIV infection that presented with chronic diarrhea.</p></div><div><h3>Material and methods</h3><p>Utilizing nonprobability consecutive convenience sampling, 24 patients were included that underwent molecular testing for the simultaneous detection of 22 pathogens.</p></div><div><h3>Results</h3><p>In 24 HIV-infected patients with chronic diarrhea, enteropathogen bacteria were detected in 69% of the cases, parasites in 18%, and viruses in 13%. Enteropathogenic <em>Escherichia coli</em> and enteroaggregative <em>Escherichia coli</em> were the main bacteria identified, <em>Giardia lamblia</em> was found in 25%, and norovirus was the most frequent viral agent. The median number of infectious agents per patient was three (range of 0 to 7). The biologic agents not identified through the FilmArray® method were tuberculosis and fungi.</p></div><div><h3>Conclusions</h3><p>Several infectious agents were simultaneously detected through the FilmArray® gastrointestinal panel in patients with HIV infection and chronic diarrhea.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 80-88"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X2300021X/pdfft?md5=55e58bfb82adf6c42ce53f4552dd8dfc&pid=1-s2.0-S2255534X2300021X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9085405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}